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Background: Carbohydrate-rich liquid drinks (CRLDs) have been recommended to attenuate insulin resistance by
shortening the preoperative fasting interval. The aim of our study the effect of preoperative oral administration of
CRLDs on the well-being and clinical status of patients.
Methods: A randomized, double blind, prospective study of patients undergoing open colorectal operations (CR)
and open cholecyctectomy (CH) was conducted. Patients were divided into three groups: study, placebo, and
control. Visual analogue scale (VAS) scores for seven parameters (thirst, hunger, anxiety, mouth dryness, nausea,
weakness and sleep quality) were recorded and compared for two different time periods (up to 24 h
postoperatively and from 36 to 48 h postoperatively). The Simplified Acute Physiology Score changes (SAPS)-II
between the three groups were also studied.
Results: There were 142 patients American Society of Anesthesiology (ASA) I or II enrolled in the study (CR = 71
and CH = 71). There were no significant differences in postoperative SAPS-II scores or lengths of hospital stay (LOS)
between the groups. However, in CR patients, the degree of thirst was partially improved by drinking CRLDs
(P = 0.027). In CH patients, on the other hand, feelings of thirst, hunger, mouth dryness, nausea and weakness
showed significant improvement (P < 0.05).
Conclusion: Oral administration of carbohydrate-rich liquid drinks (CRLDs) improves the well-being in patients
undergoing CH, but the effect is less evident in patients undergoing CR. No significant improvements were seen in
clinical status or in length of hospital stay in either group.
Trial registration: ANZCTR.org.au: ACTRN12614000995673 (registered on 16/09/2014).
Keywords: Carbohydrates, Fasting, Thirst, Preoperative use of carbohydrates, Postoperative periodBackground
Insulin resistance, as a stress inducer, is a positive pro-
tective reaction against surgery [1]. As a response to
injury (surgery), activation of neuroendocrine and in-
flammation systems occurs as a protective reaction that
initiates insulin resistance [2,3]. However, beyond a point,
this resistance begins to have negative consequences for
patient health [4,5]. One of the mechanisms to attenuate
insulin resistance is preoperative administration of
carbohydrate-rich liquid drinks (CRLDs) [6].
The more complex or lengthy the surgery, (i.e., the
severity: tissue trauma, blood loss), the more severe the* Correspondence: fatossada@hotmail.com
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unless otherwise stated.development of insulin resistance [7]. In cholecystectomy
procedures, insulin sensitivity was reduced by 56% in
one study (P < 0.01) [8] while in major colorectal sur-
gery interventions, insulin sensitivity can be reduced as
much as 90% [1].
The nothing by mouth rule (NPO) from the night before
surgery, which extends throughout the postoperative
period (can last 12–16 h), in recent years, has been under
scrutiny [9-11]. Studies have revealed that fasting can
intensify perioperative insulin resistance [12,13]. Admin-
istration of an iso-osmolar, carbohydrate rich, beverage
preoperatively is the most efficient and natural way to pro-
vide certain quantities of carbohydrates and does not pose
any threat from vomiting or aspiration if taken no sooner
than 2 h before anesthesia induction [14-16]. As a resultd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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preoperative fasting [17,18].
It has been reported also that preoperative consumption
of CRLDs reduces patient discomfort and anxiety in
the perioperative period, [19] and resulted in a shorter
hospital stay [20]. In many countries, preoperative
administration of carbohydrates is included in the
institutional protocols [21-23], although this is not
wide spread practice. These recommendations rely on
studies that have suggested that administration of carbo-
hydrates reduces metabolic stress, insulin resistance and
attenuates the nitrogen losses, [24] as well as improving
muscular strength in larger groups [25].
We designed the study to assess whether preopera-
tive oral administration of CRLDs has an impact on pa-
tient well-being, clinical status, time to regain activities
of daily living, and reduction in the length of hospital
stay, in patients undergoing open abdominal surgery
(CR, CH).
Methods
This prospective, double-blind, randomized trial was
performed between January 2010–January 2012 at the
University Clinical Center of Kosovo. Patients were
randomized into one of three groups: a study group,
placebo, and control. In this study, the placebo bever-
age was indistinguishable in appearance and taste as
possible from the special formula. For this purpose, a
colleague blinded to the rest of the study (patients,
clinical and biochemical parameters recorded during
the study) was asked to prepare and label beverages ac-
cording to the randomization codes. All other researchers
were blinded to those codes. The study group received
800 mL (per os) of carbohydrate beverage in the evening
before surgery (22:00) and an additional 400 mL 2 h
before anesthesia induction. The placebo group re-
ceived a non-caloric colorless liquid with the same
taste and without carbohydrates in the same amount as
the patients in the study group. The control group did
not receive any of these drinks and were subject to the
traditional preoperative fasting. Each procedure was
performed following the written consent obtained from
each patient. Inclusion criteria were that patients were
older than 18 years, undergoing an operation of the
colon and rectum for benign and malignant diseases,
or open abdominal cholecystectomy for chronic cholecyst-
itis. Each group of patient was analyzed and reported
separately. Exclusion criteria were type 1 or 2 diabetes
mellitus, stomach emptying disorders or documented gas-
tric esophageal reflex disease, emergency surgery interven-
tions, or refusal of the patient to participate in the trial.
The Ethics Committee of the Medical Faculty/ University
of Pristina approved the trial (protocol number: 2128, date
31.05.2010).All beverages were packed into identical bottles marked
with numbers (containing carbohydrates or placebo) by an
assigned person who did not provide the liquids to the
patients and did not take part in the evaluation of the
results. For the study group, the beverage contained
12.5% carbohydrates, 50 kcal/100 mL, 285 mOsmol/kg
(NutriciapreOp, Nutricia Ltd., Wiltshire, UK, who pro-
vided the supplements.). Patients were premedicated in
the evening before the surgery with 5 mg intramuscular di-
azepam and 0.3 ml subcutaneous Fraxiparine (Nadoparin,
GlaxoSmithKline, UK). Patients were asked to have a
regular diet for at least two days prior to admission to
the clinical ward. To achieve standardization across the
participating departments, patients had a bowel prepar-
ation with a 2 × 45 ml dose of sodium phosphate given
orally the day before surgery (at 1500 and 2000). In-
traoperative fluid management was depended on the
anesthetist’s preference. The patient was administered
prophylactic antibiotics 30 to 60 minute before the
first incision (A first or second generation cephalosporin
plus metranidazol given by i.v. route, single dose of each).
No IV fluids were given to any of the groups preopera-
tively. Anesthesia induction was performed with intra-
venous midazolam 2 mg, fentanyl (3–4 mcg/kg) and
thiopental (4–6 mg/kg). Pancuronium (0.1 mg/kg) or
atracurium (0.5 mg/kg) was used for muscular relaxation.
General anesthesia was maintained with continual propo-
fol and intermittent bolus doses of fentanyl. Postoperative
pain was treated with NSAID and tramadol hydrochloride,




Patient well-being Thirst, anxiety, hunger, mouth dry-
ness, nausea, weakness and sleep quality were assessed
using visual analogue scale (VAS) scores 1–10. [26] In
order to have a clearer picture if CHO drinks do or not
have an impact in postoperative well being of the pa-
tients VAS score questionnaire was filled twice, within
24 h following the surgery (in the morning of the first
postoperative day) and between 36 to 48 h following the
surgery (in the morning of the second postoperative
day).
Patient clinical status Clinical evaluation by the Sim-
plified Acute Physiology Score (SAPS-II), [27] was per-
formed within 24 h following the surgery. Lowest or
highest recorded BP and heart frequency following 24 h
after surgery was used to calculate SAPS II score.
Length of hospital stay The length of hospital was re-
corded for each patient.
Table 2 Demographic and other clinical data for
cholecystectomy patients- gender, age and surgery
duration were identical among the three study groups
Study Placebo Control
Gender
n (%) 22 (100) 23 (100) 26 (100)
M 6 (27) 6 (26) 8 (31)
F 16 (73) 17 (74) 18 (69)
Age (years)
Mean 55.8± 13.5 54.8± 15.1 59.1± 12.0
Surgery duration (hours)
Mean 1.2 ± 0.4 1.2± 0.3 1.3± 0.4
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Convalescence Regaining daily activities.
Data are presented using tabular presentations. Data
processing was performed using the statistical package
InStat 3 (San Diego, California, USA). The following
statistics were calculated: arithmetic mean, standard
deviation, and standard error of the mean. Minimal
and maximal values were also recorded. For statistical
testing, we used one-way analysis of variance (ANOVA)
and the Bonferroni test for multiple comparisons for para-
metric data and the Kruskal-Wallis (KW) test and the
Dunn test for multiple comparisons for non-parametric
data. Differences were significant for values of P < 0.05.
Results
There were 162 patients enrolled in the study, form
which 142 were analyzed (CR = 71 and CH = 71) (see
Additional file 1 - CONSORT diagram). All patients were
American Society of Anesthesiology (ASA) I or II. Charac-
teristics of the study, placebo and control groups are pre-
sented for CR and CH patients in Tables 1 and 2. No
statistically significant differences were found in mean
ages between the three groups in CR patients (F = 0.54,
P = 0539, P > 0.05). No statistically significant differences
in the mean duration of surgery between the CR study,
placebo and control groups (KW= 0.96, P >0.05). Also,
between the groups of CH patients no difference was
noted for demographic data (age F = 0.75, P > 0.05). The
results of VAS score comparisons for seven parameters,
0–24 h and 36–48 h postoperatively, for both the CR and
CH groups are presented in Table 3.
Colorectal group
For the six out of seven parameters of VAS scores (hunger,
anxiety, mouth dryness, nausea, fatigue and sleep quality),
we found no statistically significant differences be-
tween the groups, 0–24 h and 36–48 h after CR surgery
(P > 0.05). Multiple comparisons gave the same results for
these parameters (study group vs. placebo group, P > 0.05;Table 1 Demographic and other clinical data for colorectal
surgery patients- gender, age and surgery duration were
identical among the three study groups
Study Placebo Control
Gender
n (%) 22 (100) 23 (100) 26 (100)
M 11 (50) 9 (31.1) 13 (50)
F 11 (50) 14 (60.9) 13 (50)
Age (years)
Mean 57.9± 12.0 56.6± 13.0 53.8± 15.8
Surgery duration (hours)
Mean 3.3± 0.5 3.1± 0.4 3.1± 0.5study group vs. control group, P > 0.05; placebo group vs.
control group, P > 0.05).
During the first 24 h following the surgery, thirst was
the only parameter statistically significant different
between the placebo and control groups (KW = 7.19,
P = 0027, i.e. P < 0.05). During postoperative time interval
between 36–48 h, the only significant difference in thirst
was between the study versus control group (Table 3).
However, no significant statistical difference between
the mean values of SAPS scores were found (KW = 0.98,
P > 0.05) (Table 4). Multiple comparisons gave the same
results (study group vs. placebo group, P > 0.05; study
group vs. control group, P > 0.05; placebo group vs. control
group, P > 0.05).
LOS for the study group was 10.0 ± 3.4 days, control
group 10.1 ± 4.7 days, and placebo group 10.3 ± 2.7.
There was no significant statistical difference in the LOS
between the groups (KW= 1.67, P > 0.05). We found no
statistically significant differences in the time to return
of bowel sounds, t flatus, defecation, sitting out of bed,
oral intake, walk with assistance, walk without assistance,
or nasogastric drainage for the patients between the
groups (KW, P > 0.05), (study group vs. placebo group,
P > 0.05; study group vs. control group, P > 0.05; placebo
group vs control group, P > 0.05).
Cholecystectomy group (CH)
There were statistically significant differences (P < 0.05) in
the degree of thirst, hunger, mouth dryness, nausea and
weakness in the study group compared with the control
group in less than 24 h following the surgery, while the
differences in degree of anxiety and sleep quality were not
significant (P > 0.05) (Table 3). However, 36–48 h following
surgery, only mouth dryness was found to be significant,
when comparing study group vs. control group (P < 0.05).
The degree of anxiety, nausea, weakness and sleep quality
were not significant (P > 0.05).
Comparing study group vs. placebo group, in two time
intervals, lees then 24 h and 36–48 h there were no
Table 3 Well-being by VAS score
Colorectal patients Cholecystectomy patients
N S=22; P=23; C=24 N S=22; P=23; C=24
VAS score 0-24h, postop. 36-48h, postop. 0-24h, postop. 36-48h, postop.
S P C S P C S P C S P C
Thirst Median 3 2 4 2 1 2 3 2 4 2 1 2
Min 1 1 1 1 1 1 1 1 1 1 1 1
Max 5 5 7 3 3 5 5 5 7 3 3 5
Gr. S vs. Gr. P; P>0.05 Gr. S vs. Gr. P; P>0.05 Gr. S vs. Gr. P; P>0.05 Gr. S vs. Gr. P; P>0.05
Gr. S vs. Gr. C; P>0.05 Gr. S vs. Gr. C; P<0.05 Gr. S vs. Gr. C; P<0.05 Gr. S vs. Gr. C; P>0.05
Gr. P vs. Gr. C; P<0.05 Gr. P vs. Gr. C; P>0.05 Gr. P vs. Gr. C; P<0.05 Gr. P vs. Gr. C; P<0.05
Hunger Median 3 3 4 2 2 3 3 2 4 2 2 3
Min 1 1 1 1 1 1 1 1 1 1 1 1
Max 5 5 8 4 4 6 5 5 8 4 4 6
Gr. S vs. Gr. P; P>0.05 Gr. S vs. Gr. P; P>0.05 Gr. S vs. Gr. P; P>0.05 Gr. S vs. Gr. P; P>0.05
Gr. S vs. Gr. C; P>0.05 Gr. S vs. Gr. C; P>0.05 Gr. S vs. Gr. C; P<0.05 Gr. S vs. Gr. C; P>0.05
Gr. P vs. Gr. C; P>0.05 Gr. P vs. Gr. C; P>0.05 Gr. P vs. Gr. C; P<0.05 Gr. P vs. Gr. C; P>0.05
Anxiety Median 3 1 2 1 1 1.5 2 1 2 1 1 1.5
Min 1 1 1 1 1 1 1 1 1 1 1 1
Max 3 4 6 3 3 5 3 4 6 3 3 5
Gr. S vs. Gr. P; P>0.05 Gr. S vs. Gr. P; P>0.05 Gr. S vs. Gr. P; P>0.05 Gr. S vs. Gr. P; P>0.05
Gr. S vs. Gr. C; P>0.05 Gr. S vs. Gr. C; P>0.05 Gr. S vs. Gr. C; P>0.05 Gr. S vs. Gr. C; P>0.05
Gr. P vs. Gr. C; P>0.05 Gr. P vs. Gr. C; P>0.05 Gr. P vs. Gr. C; P>0.05 Gr. P vs. Gr. C; P>0.05
Mouth dryness Median 5 4 6 2 2 3 5 4 6 2 2 3
Min 3 3 3 1 1 1 3 3 3 1 1 1
Max 7 7 9 4 4 5 7 7 9 4 4 5
Gr. S vs. Gr. P; P>0.05 Gr. S vs. Gr. P; P>0.05 Gr. S vs. Gr. P; P>0.05 Gr. S vs. Gr. P; P>0.05
Gr. S vs. Gr. C; P>0.05 Gr. S vs. Gr. C; P<0.05 Gr. S vs. Gr. C; P<0.05 Gr. S vs. Gr. C; P<0.05
Gr. P vs. Gr. C; P>0.05 Gr. P vs. Gr. C; P>0.05 Gr. P vs. Gr. C; P<0.05 Gr. P vs. Gr. C; P<0.05
Nausea Median 1 3 2.5 1 2 2 1 3 2.5 1 2 2
Min 1 1 1 1 1 1 1 1 1 1 1 1
Max 5 6 6 3 3 5 5 6 6 3 3 5
Gr. S vs. Gr. P; P>0.05 Gr. S vs. Gr. P; P>0.05 Gr. S vs. Gr. P; P>0.05 Gr. S vs. Gr. P; P>0.05
Gr. S vs. Gr. C; P>0.05 Gr. S vs. Gr. C; P<0.05 Gr. S vs. Gr. C; P<0.05 Gr. S vs. Gr. C; P>0.05
Gr. P vs. Gr. C; P>0.05 Gr. P vs. Gr. C; P>0.05 Gr. P vs. Gr. C; P>0.05 Gr. P vs. Gr. C; P>0.05
Weakness Median 4 3 3 1 2 3 4 3 3 2 2 3
Min 1 1 1 1 1 2 1 1 1 1 1 1
Max 6 6 6 3 4 4 6 6 6 5 4 4
Gr. S vs. Gr. P; P>0.05 Gr. S vs. Gr. P; P>0.05 Gr. S vs. Gr. P; P>0.05 Gr. S vs. Gr. P; P>0.05
Gr. S vs. Gr. C; P<0.05 Gr. S vs. Gr. C; P>0.05 Gr. S vs. Gr. C; P<0.05 Gr. S vs. Gr. C; P>0.05
Gr. P vs. Gr. C; P>0.05 Gr. P vs. Gr. C; P>0.05 Gr. P vs. Gr. C; P>0.05 Gr. P vs. Gr. C; P>0.05
Sleep quality Median 3 3 3.5 2 3 3 3 3 3.5 2 3 3
Min 1 1 1 1 1 1 1 1 1 1 1 1
Max 5 7 6 5 5 6 5 7 6 5 5 6
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Table 3 Well-being by VAS score (Continued)
Gr. S vs. Gr. P; P>0.05 Gr. S vs. Gr. P; P>0.05 Gr. S vs. Gr. P; P>0.05 Gr. S vs. Gr. P; P>0.05
Gr. S vs. Gr. C; P>0.05 Gr. S vs. Gr. C; P>0.05 Gr. S vs. Gr. C; P>0.05 Gr. S vs. Gr. C; P>0.05
Gr. P vs. Gr. C; P>0.05 Gr. P vs. Gr. C; P>0.05 Gr. P vs. Gr. C; P>0.05 Gr. P vs. Gr. C; P>0.05
For each evaluation statistic, the bold numbers denotes significant statistical difference.
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parameters.
LOS for the study group was 4.4 ± 0.8 days, control
group 4.4 ± 1.0 days, and placebo group 4.6 ± 1.1. There
was no significant statistical difference in the LOS between
the groups (KW= 2.0, P > 0.05). In addition, the SAPS II
score and recovery time were not statistically different be-
tween the groups (study group vs. placebo group; P > 0.05,
study group vs. control group; P > 0.05, placebo group vs.
control group; P > 0.05).
Discussion
We have attempted to answer the question if the post-
operative well-being of the patients is improved by the
preoperative administration of CRLDs. While, thirst was
the only parameter that was improved in patients under-
going colorectal surgery, all other well-being parameters
of VAS score were not affected. However, in patients
undergoing open cholecystectomy, our data reveal that
the postoperative well-being of patients who received
CRLDs in the preoperative period improved five out of
seven well-being parameters (thirst, hunger, mouth dry-
ness, nausea and weakness) when compared the study
group vs. control group, or for three parameters when
compared the placebo group vs. control group (P < 0.05).
Attenuated thirst and a reduced need for perioperative
administration of inotropic drugs when taking CRLDs
have been observed in patients undergoing open heart
surgery interventions [28]. Hausel and colleagues, [14]Table 4 The parameters of SAPS II score values by group
in colorectal patients- clinical evaluation by SAPS-II was
performed within 24 h following the surgery
SAPS II score Study Gr. Placebo Gr. Control Gr.
Number of patients 22 23 23
Mean 13.0 12.1 11.0
SD 6.5 6.6 7.8
SEM 1.39 1.37 1.62
Min 0 0 0
Max 29 23 32
Kruskal Wallis test KW=0.98, P>0.05
Dunn Multiple Comparisons Test S. Gr. vs. P. Gr.; P>0.05
S. Gr. vs. C. Gr.; P>0.05
P. Gr. vs. C. Gr.; P>0.05
Gr. S: study group, Gr. P: placebo group, Gr. C: control group.utilizing VAS for patients categorized under ASA I–II
undergoing abdominal surgery (n = 252), found no dif-
ferences between the groups (CHO and placebo) in the
degree of thirst, although there was a significant differ-
ence compared with the control group. However, in the
same study it was reported that patients who received
CRLDs experienced a significant reduction in anxiety
and hunger.
In our study there was no difference in SAPS II score
or length of hospital stay, and other clinical data were
the same for both patients undergoing colorectal and
cholecystectomy operations. In contrast to the results of
this study, De Aguilar-Nascimento and colleagues con-
ducted a study of 60 female patients undergoing chole-
cystectomy, patients with carbohydrates intake had
reduced gastrointestinal discomfort (vomiting and ab-
dominal distension), as well as a shorter hospital stay
[29]. Furthermore, intake of these drinks, which reduces
preoperative fasting, demonstrated positive effects on
thirst, hunger, perioperative anxiety and muscular strength
[29,24]. On the other hand, Henriksen and colleagues re-
ported results from a small study (n = 48) prior to elective
bowel resection, in which their patients showed no dif-
ferences, even for thirst [27]. In contrast our data, as
reported elsewhere [30], show that thirst, as a main
component in preoperative discomfort, is effectively
reduced by the intake of clear liquids. In addition, in
minor surgeries such is laparoscopic cholecystectomy,
another study showed no differences in postoperative
sleep or well-being, [31] while yet another study indicated
less nausea and vomiting for the group with carbohydrate
intake compared with fasting patients [32].
An important question arises from our study: why did
the study group have greater improvement in patients
undergoing cholecystectomy than those undergoing colo-
rectal surgical interventions when taking CRLDs? Results
varied between different patients population, investigating
the same parameters. In both/different types of surgical
operations on patients with varying postoperative insulin
resistance the results have been inconsistent. In colorectal
operations, which result in more insulin resistance, there
were no significantly different results compared with
cholecystectomy operations where well-being parameters
were statistically different in a positive way for patients
drinking a carbohydrate versus control group. Reason
might be longer duration of operation in colorectal group
where there was enough time to replace volume deficit
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period both groups were equally balanced with fluids. This
didn’t happen in cholecystectomy operations due to
shorter length of operation. This is only an assumption
since measuring IV volume loading during operation was
not a part of this study. In this study, also majority of
results when comparing study group vs. placebo group do
not show any significant difference. There are other stud-
ies that do have similar results such as Mathur et al. were
CHO treatment did not improve postoperative fatigue or
length of hospital stay after major abdominal surgery, [33]
or Hausael at al. found no differences between the groups
(CHO and placebo) in the degree of thirst [14]. This might
bring us to hypothesis that volume of oral fluids taken is
more important than the energy that they posses based on
carbohydrate concentration.Study limitations
This study has its own limitations. It is limited by small
sample size e.g. small number of patients per group.
Approval from Ethical Committee for the study to last
two years, limited the number of patients included in
research.
Although previous authors [1,7,8] talk about difference
in insulin resistance in colorectal operations and in
cholecystectomy operation, in our study we did not
measure insulin resistance or insulin levels since it was
not our aim. We measured glucose levels in blood pre and
postoperatively as part of routine lab for this project.Conclusions
Preoperative oral intake of carbohydrates yields different
postoperative well-being (VAS) scores for patients
undergoing different operations. The only positive ef-
fect on patients undergoing colorectal operations was
an attenuation of thirst (36–48 h postoperatively). For
patients undergoing cholecystectomy operations, the
VAS score was significantly better in patients taking
carbohydrate drinks for thirst, hunger, mouth dryness,
nausea and weakness. Other aspects studied showed
no significant differences among the study group, control
group or the placebo group regardless of the type of oper-
ation, e.g. clinical status (SAPS-II score), patient convales-
cence and the length of hospital stay.Additional file
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